[Ventricular arrhythmias after myocardial infarction: risk classification and treatment concepts].
Seidl
K
K
Medizinische Klinik B (Kardiologie) des Herzzentrums Ludwigshafen.
Hauer
B
B
Schwick
N
N
Buechele
T
T
Schilling
I
I
Senges
J
J
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D017147:Defibrillators, Implantable; D004562:Electrocardiography; D005080:Exercise Test; D006339:Heart Rate; D006352:Heart Ventricles; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000150:complications* / Q000401:mortality / Q000503:physiopathology; D011446:Prospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D017180:Tachycardia, Ventricular / Q000209:etiology; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000638:Amiodarone
Ventrikuläre Arrhythmien nach Myokardinfarkt. Risikoeinstufung und Therapiekonzepte.